HERON THERAPEUTICS, INC. /DE/ — Director's Dealing 2021

Apr 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK: 0000818033
Period of Report: 2015-06-20

Reporting Person: Quart Barry D (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-06-20	Common Stock	J	600	$0.00	Acquired	600	Indirect
2016-11-04	Common Stock	G	600	$0.00	Disposed	0	Indirect
2016-11-04	Common Stock	G	600	$0.00	Acquired	92509	Direct
2021-04-13	Common Stock	M	3646	—	Acquired	96155	Direct
2021-04-13	Common Stock	F	963	$16.66	Disposed	95192	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-13	Restricted Stock Units	$	M	3646	Disposed		Common Stock (3646)	Direct

Footnotes

F1: The reporting person acquired indirect ownership of the shares upon marriage to the reporting person's spouse on June 20, 2015. The shares were inadvertently omitted from prior Form 4 filings.

F2: Represents transfer of shares by the reporting person's spouse to an account jointly held by the reporting person. The shares were inadvertently omitted from prior Form 5 filings.

F3: Restricted stock units convert into common stock on a one-for-one basis.

F4: Represents the withholding by the Company of certain of the vested shares of restricted stock units to satisfy the minimum statutory tax obligations applicable to such transactions.

F5: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020).